REPORT ID 3753

EMEA (Europe, Middle East and Africa) Anti-Obesity Prescription Drugs Market Report 2017

Publish Date
14-Dec-17
Pages
106
Format
Electronic (PDF)

In this report, the EMEA Anti-Obesity Prescription Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Anti-Obesity Prescription Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Anti-Obesity Prescription Drugs market competition by top manufacturers/players, with Anti-Obesity Prescription Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    VIVUS
    Orexigen Therapeutics
    Novo Nordisk
    F Hoffmann La Roche
    Arena Pharmaceuticals
    ...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Bupropion and Naltrexone
    Orlistat
    Lorcaserin
    Phentermine and Topiramate
    Liraglutide

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospitals Pharmacies
    Retail Pharmacies
    E-commerce

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Anti-Obesity Prescription Drugs Market Report 2017
1 Anti-Obesity Prescription Drugs Overview
    1.1 Product Overview and Scope of Anti-Obesity Prescription Drugs
    1.2 Classification of Anti-Obesity Prescription Drugs
        1.2.1 EMEA Anti-Obesity Prescription Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Anti-Obesity Prescription Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Bupropion and Naltrexone
        1.2.4 Orlistat
        1.2.5 Lorcaserin
        1.2.6 Phentermine and Topiramate
        1.2.7 Liraglutide
    1.3 EMEA Anti-Obesity Prescription Drugs Market by Application/End Users
        1.3.1 EMEA Anti-Obesity Prescription Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospitals Pharmacies
        1.3.3 Retail Pharmacies
        1.3.4 E-commerce
    1.4 EMEA Anti-Obesity Prescription Drugs Market by Region
        1.4.1 EMEA Anti-Obesity Prescription Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Anti-Obesity Prescription Drugs (2012-2022)
        1.5.1 EMEA Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Anti-Obesity Prescription Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Anti-Obesity Prescription Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Anti-Obesity Prescription Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Anti-Obesity Prescription Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Anti-Obesity Prescription Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Anti-Obesity Prescription Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Anti-Obesity Prescription Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Anti-Obesity Prescription Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Anti-Obesity Prescription Drugs (Volume) by Application
    2.4 EMEA Anti-Obesity Prescription Drugs (Volume and Value) by Region
        2.4.1 EMEA Anti-Obesity Prescription Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Anti-Obesity Prescription Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Anti-Obesity Prescription Drugs Sales Price by Region (2012-2017)

3 Europe Anti-Obesity Prescription Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Anti-Obesity Prescription Drugs Sales and Value (2012-2017)
        3.1.1 Europe Anti-Obesity Prescription Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Anti-Obesity Prescription Drugs Sales and Market Share by Type
    3.3 Europe Anti-Obesity Prescription Drugs Sales and Market Share by Application
    3.4 Europe Anti-Obesity Prescription Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Anti-Obesity Prescription Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Anti-Obesity Prescription Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)

4 Middle East Anti-Obesity Prescription Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Anti-Obesity Prescription Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Anti-Obesity Prescription Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Anti-Obesity Prescription Drugs Sales and Market Share by Type
    4.3 Middle East Anti-Obesity Prescription Drugs Sales and Market Share by Application
    4.4 Middle East Anti-Obesity Prescription Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Anti-Obesity Prescription Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Anti-Obesity Prescription Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)

5 Africa Anti-Obesity Prescription Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Anti-Obesity Prescription Drugs Sales and Value (2012-2017)
        5.1.1 Africa Anti-Obesity Prescription Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Anti-Obesity Prescription Drugs Sales and Market Share by Type
    5.3 Africa Anti-Obesity Prescription Drugs Sales and Market Share by Application
    5.4 Africa Anti-Obesity Prescription Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Anti-Obesity Prescription Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Anti-Obesity Prescription Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)

6 EMEA Anti-Obesity Prescription Drugs Manufacturers/Players Profiles and Sales Data
    6.1 VIVUS
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 VIVUS Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Orexigen Therapeutics
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novo Nordisk
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novo Nordisk Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 F Hoffmann La Roche
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Arena Pharmaceuticals
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    ...

7 Anti-Obesity Prescription Drugs Manufacturing Cost Analysis
    7.1 Anti-Obesity Prescription Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Anti-Obesity Prescription Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Anti-Obesity Prescription Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Anti-Obesity Prescription Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Anti-Obesity Prescription Drugs Market Forecast (2017-2022)
    11.1 EMEA Anti-Obesity Prescription Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Anti-Obesity Prescription Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Anti-Obesity Prescription Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Anti-Obesity Prescription Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Anti-Obesity Prescription Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Anti-Obesity Prescription Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer